A long-term study has identified a potential biomarker that could help detect which patients are progressing toward more severe forms of multiple sclerosis.

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.

Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year survival rate of only 5%.

Acute systemic inflammation has long been suspected to trigger harmful processes within the brain, contributing to neurodegenerative disorders such as ...

An experimental drug developed at Northwestern University has demonstrated further promise as an early intervention for Alzheimer's disease.

Coya Therapeutics Inc. has released results of a study designed to evaluate the effects of COYA-303 (low dose IL-2 and a GLP-1 receptor agonist) in an established in vivo lipopolysaccharide mouse ...

Overactive immune response disrupts brain function before neuronal damage occurs. Tracking urea levels and nerve cell markers ...

Multiple sclerosis, often called MS, is a long-lasting disease that affects the brain and spinal cord. It happens when the ...